Calcitonin

American Journal of the Medical Sciences

Volumn 313, Issue 1, 1997, Pages 13-16

  Silverman, Stuart L ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Osteoporosis Medical Center   (United States)

^c Rheumatology Division   (United States)

Author keywords

Calcitonin; Osteoporosis therapy

Indexed keywords

CALCITONIN; PLACEBO;

ADULT; AGED; ALLERGIC REACTION; ARTICLE; BONE MASS; COST BENEFIT ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; EPISTAXIS; FEMALE; HUMAN; INTRANASAL DRUG ADMINISTRATION; LUMBAR SPINE; POSTMENOPAUSE OSTEOPOROSIS; RHINITIS; TREATMENT PLANNING;

EID: 0031032044     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-199701000-00003     Document Type: Article

References (26)

1. Chambers TJ, Moore A, The sensitivity of isolated osteoclasts to morphological transformation by calcitonin. J Clin Endocrinol Metab. 1983;57:819-24.
2. Wallach S, Farley JR, Baylink DJ, Brenner-Gate L. Effects of calcitonin on bone quality and osteoblastic function. Calcif Tissue Int. 1993;52:335-9.
3. Geusens P, Nijs J, Jiang Y, Caulin F, Van Audedercke R, Van der Perre G, Goovaerts S, Gielen J, Marchal G, Dequeker J. Bone mass, density, and strength in ovariectomized sheep treated with salmon calcitonin. In: Christiansen C, Overgaard K; eds. Osteoporosis 1990, Osteopress ApS, 1990:1152-3.
4. Overgaard K, Hansen MA, Jensen SB, et al. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: A dose response study. British Medical Journal. 1992;305:556-61.
5. Rico H, Revilla M, Hernandez ER, Villa LF, Alvarez de Buergo M. Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: A prospective study. Calcif Tissue Int. 1995;56:181-5.
6. Nagant de Deuxchaisnes C. Use of calcitonin in the treatment of postmenopausal osteoporosis. In: DeLuca, Mazess; eds, Osteoporosis: Physiological Basis, Assessment and Treatment. New York: Elsevier; 1989;247-58.
7. Cranney A, Moher D, Shea B, Welld G, Adachi R, Tugwell P. Metanalysis of calcitonin in the treatment of postmenopausal osteoporosis (PMO). Arthritis Rheum. 1995;38:S360.
8. Gennari C, Passeri M, Chierichetti SM, Piolini M, Side effects of synthetic salmon and human calcitonin. Lancet. 1983;I:594-5.
9. Overgaard K, Riss BJ, Christiansen K, Podenphant J, Johansen JS. Nasal calcitonin for the treatment of established osteoporosis. Clin Endocrinol. 1989;30:435-43.
10. Overgaard K, Lindsay R, Christiansen C. Patient responses to calcitonin salmon nasal spray: A subanalysis of a 2-year study. Clin Ther. 1995;17(4):680-5.
11. Ellerington MC, Hillard, Whitcroft SJ, Marsh MS, Lees B, Banks LM, Whitehead MI, Stevenson JC. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis. Calcif Tissue Int. 1996;59(1):6-11.
12. Kanis JA, Johnell O, Gulberg B, Allander E, Dilsen G, Genuari C, Lopez Vas AA, Lyritis BP, Mazzuoli G, Miravet L, Passeri M, Perez Cano R, Rapado A, Ribor C. Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture, British Medical Journal. 1992;305;1124-8.
13. Civitelli R, Gonnelli S, Zacchei F, Bigazzi S, Vattimo A, Avioli LV, Gennari C. Bone turnover in postmenopausal osteoporosis: Effect of calcitonin treatment, J Clin Invest. 1988;82:1268-74.
14. Kraenzlin ME, Seibel MJ, Trechsel U, Boerlin V, Azria M, Kraenzlin CA, Haas HG. The effect of intranasal salmon calcitonin on, pogtmenopausal bone turnover as assessed by biochemical markers: Evidence of maximal effect after 8 weeks of continuous treatment. Calcif Tissue Int. 1996; 68:216-20.
15. Sambrook P, Birmingham J, Kelly P, Kempler S, Nguyen T, Pocock N, Eisman J. Prevention of corticosteroid osteoporosis, N Engl J Med. 1903;328:1781-2.
16. Campodarve I, Drinkwater BL, Insogna KL, Johnston C, Lang B, Lindsay R, Neer B, Slovak DM, Gaich G, Procaccini R, Chesnut CH. Intranasal salmon calcitonin (INSC), 50-200 IU does not prevent bone loss in early postmenopausal women (abstract). J Bone Min Res. 1994; 9(suppl 1):S391.
17. Azria M. The calcitonins: Physiology and pharmacology. Karrger Basel. 1989.
18. Azria M, Copp DH, Zanelli JM. 25 years of salmon calcitonin: from synthesis to therapeutic use, Calcif Tissue Int. 1995;57:405-8.
19. Binge JD, Welzel D. Salmon calcitonin in the therapy of corticosteroid induced osteoporosis. Eur J Clin Pharmacol. 1987;33:35-9.
20. Montemurro L, Sohiraldi G, Fraoli P, Tosi G, Riboldi A, Pizzato G. Prevention of corticosteroid induced osteoporosis with salmon calcitonin in sarcoid patients, Calcif Tissue Int. 1991;49:71-6.
21. Luengo M, Picado C, Del Rio L, Guanaberes N, Montserrat JM, Setoain J. Treatment of steroid induced osteopenia with calcitonin in corticosteroid dependent asthma. American Review Respiratory Disease. 1990; 142:104.
22. Pun KK, Chan LWL. Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures. Clin Ther. 1989:11:205-9.
23. Foti R, Martorana U, Broggini ML Long-term tolerability of nasal spray formulation of salmon calcitonin. Current Therapeutic Research. 1995;56:429-35.
24. Singer F, S Alfred JP, Neer AM, Krane SM, Potts JT, Bloch KJ. An evaluation of antibodies and clinical resistance to salmon calcitonin. J Clin Invest, 1972;51:2331-8.
25. Reginster JY, Gennari C, Mautalen C, Deroisy R, Denis D, Lecart MP, Vandalem JL, Collete J, Franchimont P. Influence of specific anti-salmon calcitonin antibodies on biological effectiveness of nasal salmon calcitonin in Paget's disease of bone. Scand J Rheumatol. 1990;19:83-6.
26. Meschia M, Brincat M, Barbaraoini P, Carena Maiai, M, Marri R, Crosignani PG. Effect of hormone replacement therapy and calcitonin on bone mass in postmenopausal women. Eur J Obstet Gynecol Reprod Biol. 1992;47:53-7.